# Antibiotic intermediates (6-APA, 7-ACA): Cycles

How Chinese price cuts met India's new plants

Source page: https://www.materialinsights.org/chemicals/antibiotic_intermediates/cycles/

How Chinese price cuts met India's new plants What this tab covers How its prices and margins move: past booms and busts with price levels, the spread or margin that the industry watches, the drivers of the cycle and the metrics to track.

Prices for penicillin G and 6-APA are set by a few Chinese groups and swing with their capacity additions, environmental closures and export pricing. When India announced PLI, Chinese prices for some APIs fell 40-50%, which Indian officials and producers describe as targeted pricing. The floor is the Chinese cash cost, driven by power and maize; India's 2026 MIP effectively sets the domestic floor at Rs 2,216-3,405/kg.
 The spread to watch **6-APA minus 1.7 x penicillin G cost**

At MIP levels: Rs 3,405 minus 1.72 x Rs 2,216 is negative (about minus Rs 400/kg), so integrated producers capture value across both steps rather than by buying penicillin G at MIP (derived; MIPs are floors, not traded prices).

#### Booms and busts

1. 1990s-2000s

Chinese fermentation scale-up undercut Indian producers, who closed penicillin G plants.

not published (indicative history)

2. 2017-2018

Chinese environmental inspections tightened antibiotic intermediate supply.

not published

3. 2020-2024

After India's PLI (2020), Chinese import volumes rose 30-45% for some APIs and prices fell 40-50%.

IndraStra citing PIB (2026)

4. 2026

India set MIPs (Jan) and DGTR opened probes on penicillin G, 6-APA and amoxicillin (Sept), with investigation period April 2025 to March 2026.

MIP Rs 2,216/kg penicillin G potassium, Rs 3,405/kg 6-APA, Rs 2,733/kg amoxicillin

#### What drives the cycle

- **Chinese capacity and pricing.** A few groups set world prices.
- **Power and maize costs.** Fermentation is energy- and sugar-intensive.
- **Indian trade remedies.** MIP and duties decide Lyfius and Qule viability.
- **Antibiotic stewardship and AMR policy.** Could slow volume growth.

#### Metrics to track

| Metric | Why it matters | Where to track it |
|---|---|---|
| **DGTR findings on penicillin G, 6-APA, amoxicillin** | duty decisions due 2027 | DGTR |
| **Aurobindo results commentary on Lyfius** | utilisation and margins | Aurobindo quarterly results |
| **Penicillin G transaction prices** | market level | Pharmaoffer |

## Other sections

- [Summary](https://www.materialinsights.org/chemicals/antibiotic_intermediates/index.md)
- [Overview](https://www.materialinsights.org/chemicals/antibiotic_intermediates/overview/index.md)
- [Correlation](https://www.materialinsights.org/chemicals/antibiotic_intermediates/correlation/index.md)
- [Production route](https://www.materialinsights.org/chemicals/antibiotic_intermediates/routes/index.md)
- [Production](https://www.materialinsights.org/chemicals/antibiotic_intermediates/production/index.md)
- [Feedstocks](https://www.materialinsights.org/chemicals/antibiotic_intermediates/feedstocks/index.md)
- [Trading](https://www.materialinsights.org/chemicals/antibiotic_intermediates/trading/index.md)
- [Movement](https://www.materialinsights.org/chemicals/antibiotic_intermediates/movement/index.md)
- [Regulation](https://www.materialinsights.org/chemicals/antibiotic_intermediates/regulation/index.md)
- [Characteristics](https://www.materialinsights.org/chemicals/antibiotic_intermediates/characteristics/index.md)
- [Emissions](https://www.materialinsights.org/chemicals/antibiotic_intermediates/emissions/index.md)
- [Relationships](https://www.materialinsights.org/chemicals/antibiotic_intermediates/links/index.md)